Brief: Enzychem Lifesciences Announces Plans To Advance Clinical Trial In South Korea For EC-18 As A Potential Therapeutic For COVID-19 Infection
17/03/2020 19:36
March 17 (Reuters) - Enzychem Lifesciences Corp 183490.KQ :
* ENZYCHEM LIFESCIENCES ANNOUNCES PLANS TO ADVANCE CLINICAL
TRIAL
IN SOUTH KOREA FOR EC-18 AS A POTENTIAL THERAPEUTIC FOR COVID-19
INFECTION
* ENZYCHEM LIFESCIENCES - BEEN IN COMMUNICATION WITH
RELEVANT
U.S. GOVERNMENT AUTHORITIES FOR DEVELOPMENT COLLABORATION FOR
CORONAVIRUS TREATMENT
* ENZYCHEM LIFESCIENCES - ADVANCING RESEARCH COLLABORATION
FOR
DEVELOPMENT OF EC-18 WITH VARIOUS GOVERNMENT AUTHORITIES OF
CHINA & KOREA
Source text for Eikon: ID:nPn9dv7wta
Further company coverage: 183490.KQ
((reuters.briefs@thomsonreuters.com;))
Recent news on Enzychem Lifesciences
See all newsBrief: Enzychem Lifesciences To Divest 8 Billion Won Worth Of Own Shares
Brief: Enzychem Lifesciences Announces Completion Of Clinical Study Report (Csr) For Phase 2 Study Of Ec-18 In Chemoradiation-Induced Oral Mucositis
South Korea's Enzychem to make Indian drugmaker Cadila's COVID-19 shot (updated)
Brief: Cadila Healthcare Inks Deal With South Korea's Enzychem For Plasmid DNA Vaccine
South Korea's Enzychem to make Indian drugmaker Cadila's COVID-19 shot